Related Experiment Video
Updated: Mar 26, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification
Duk-Hwa Kwon1, Gwang Hyeon Eom1, Jeong Hyeon Ko1
1Department of Pharmacology and Medical Research Center for Gene Regulation, Chonnam National University Medical School, 5 Hak-dong, Dong-ku, Gwangju 501-746, Republic of Korea.
Abstract:
Vascular calcification (VC) is often associated with cardiovascular and metabolic diseases. However, the molecular mechanisms linking VC to these diseases have yet to be elucidated. Here we report that MDM2-induced ubiquitination of histone deacetylase 1 (HDAC1) mediates VC. Loss of HDAC1 activity via either chemical inhibitor or genetic ablation enhances VC. HDAC1 protein, but not mRNA, is reduced in cell and animal calcification models and in human calcified coronary artery. Under calcification-inducing conditions, proteasomal degradation of HDAC1 precedes VC and it is mediated by MDM2 E3 ubiquitin ligase that initiates HDAC1 K74 ubiquitination. Overexpression of MDM2 enhances VC, whereas loss of MDM2 blunts it. Decoy peptide spanning HDAC1 K74 and RG 7112, an MDM2 inhibitor, prevent VC in vivo and in vitro. These results uncover a previously unappreciated ubiquitination pathway and suggest MDM2-mediated HDAC1 ubiquitination as a new therapeutic target in VC.
Insights
MDM2-induced ubiquitination of histone deacetylase 1 (HDAC1) drives vascular calcification. Inhibiting this process, by targeting MDM2 or HDAC1, offers a new therapeutic strategy for cardiovascular and metabolic diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- Vascular calcification (VC) is linked to cardiovascular and metabolic diseases, but its molecular drivers are unclear.
- Understanding the mechanisms of VC is crucial for developing effective treatments.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying vascular calcification.
- To identify novel therapeutic targets for VC.
Main Methods:
- Investigated the role of histone deacetylase 1 (HDAC1) and MDM2 in VC using cell and animal models.
- Utilized chemical inhibitors and genetic ablation to study HDAC1 and MDM2 function.
- Examined HDAC1 ubiquitination at K74 and its proteasomal degradation.
Main Results:
- Loss of HDAC1 activity exacerbates VC.
- HDAC1 protein levels decrease in VC models and human calcified arteries.
- MDM2 E3 ubiquitin ligase mediates HDAC1 ubiquitination at K74, leading to its proteasomal degradation and promoting VC.
- MDM2 overexpression enhances VC, while MDM2 inhibition or decoy peptides targeting HDAC1 K74 reduce VC.
Conclusions:
- MDM2-mediated ubiquitination and degradation of HDAC1 is a key pathway in vascular calcification.
- Targeting the MDM2-HDAC1 ubiquitination axis presents a promising therapeutic strategy for VC and associated diseases.
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Abnormal Proliferation
Anaphase Promoting Complex
Regulation of Angiogenesis and Blood Supply

